Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.36 (
hyaluronidase
)
4,606
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A commercial preparation of a sodium polystyrene sulfonate (designated as N-
PSS
; its molecular weight is 500000 daltons) was tested as an inhibitor of sperm function and as a preventive agent for conception and the transmission of sexually transmitted diseases. The polymer is an irreversible inhibitor of
hyaluronidase
and acrosin; its IC50 values are 5.7 microg/mL and 0.5 microg/mL, for
hyaluronidase
and acrosin, respectively. N-
PSS
is also a stimulus of human sperm acrosomal loss. It produces maximal acrosomal loss at 2.5 microg/mL. Contraception in rabbits is nearly complete when rabbit spermatozoa are pretreated with 0.5 mg/mL of N-
PSS
before artificial insemination; however, N-
PSS
does not immobilize spermatozoa at concentrations as high as 50 mg/mL. N-
PSS
has broad spectrum antiviral and antibacterial activities. Infection by human immunodeficiency virus and herpes simplex virus are inhibited by N-
PSS
; 3-log reductions are produced by 7 microg/mL and 3 microg/mL, respectively. N-
PSS
is active against Chlamydia trachomatis and Neisseria gonorrhoeae. At 1 mg/mL, N-
PSS
inhibits chlamydial infectivity by more than 90%. N-
PSS
produces a 3-log reduction in gonococcal growth at 15 microg/mL. In contrast, N-
PSS
(5 mg/mL) does not affect the growth of Lactobacillus (normal component of the vaginal flora). N-
PSS
can be classified as a noncytotoxic contraceptive antimicrobial agent. These properties justify bringing a polystyrene sulfonate into clinical trials for its evaluation as a preventive agent for conception and several sexually transmitted diseases.
...
PMID:Evaluation of poly(styrene-4-sulfonate) as a preventive agent for conception and sexually transmitted diseases. 1110 13
Host cell infection by sexually transmitted disease (STD)-causing microbes and fertilization by spermatozoa may have some mechanisms in common. If so, certain noncytotoxic agents could inhibit the functional activity of both organisms. High molecular mass poly(sodium 4-styrenesulfonate) (T-
PSS
) may be one of these compounds. T-
PSS
alone (1 mg/ml) or in a gel (2% or 5% T-
PSS
) completely prevented conception in the rabbit. Contraception was not due to sperm cytotoxicity or to an effect on sperm migration. However, T-
PSS
inhibited sperm
hyaluronidase
(IC(50) = 5.3 microg/ml) and acrosin (IC(50) = 0.3 microg/ml) and caused the loss of acrosomes from spermatozoa (85% maximal loss by 0.5 microg/ml). T-
PSS
(5% in gel) also reduced sperm penetration into bovine cervical mucus (73% inhibition by 1 mg gel/ml). T-
PSS
(5% in gel) inhibited human immunodeficiency virus (HIV; IC(50)= 16 microg gel/ml) and herpes simplex viruses (HSV-1 and HSV-2; IC(50) = 1.3 and 1.0 microg gel/ml, respectively). The drug showed high efficacy against a number of clinical isolates and laboratory strains. T-
PSS
(5% in gel) also inhibited Neisseria gonorrhea (IC(50) < 1.0 gel/ml) and Chlamydia trachomatis (IC(50) = 1.2 microg gel/ml) but had no effect on lactobacilli. These results imply that T-
PSS
is an effective functional inhibitor of both spermatozoa and certain STD-causing microbes. The noncytotoxic nature should make T-
PSS
safe for vaginal use. T-
PSS
was nonmutagenic in vitro and possessed an acute oral toxicity of >5 g/kg (rat). Gel with 10% T-
PSS
did not irritate the skin or penile mucosa (rabbit) and caused no dermal sensitization (guinea pig). Vaginal administration of the 5% T-
PSS
gel to the rabbit for 14 consecutive days caused no systemic toxicity and only mild (acceptable) vaginal irritation. T-
PSS
in gel form is worthy of clinical evaluation as a vaginal contraceptive HIV/STD preventative.
...
PMID:Efficacy and safety of a new vaginal contraceptive antimicrobial formulation containing high molecular weight poly(sodium 4-styrenesulfonate). 1190 5